Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for OTL-200

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

The Company intends to use the net proceeds to accelerate commercialization of Libmeldy and advance the company’s HSC gene therapy R&D portfolio and approval of OTL-200 in the U.S. for metachromatic leukodystrophy (MLD), advancing its clinical and pre-clinical stage programs.


Lead Product(s): OTL-200

Therapeutic Area: Genetic Disease Product Name: OTL-200

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $188.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement March 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FDA has cleared the company’s Investigational New Drug application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy.


Lead Product(s): OTL-200

Therapeutic Area: Genetic Disease Product Name: OTL-200

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 19, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Orchard’s investigational ex vivo hematopoietic stem cell (HSC) gene therapies in the upcoming years.


Lead Product(s): OTL-200

Therapeutic Area: Genetic Disease Product Name: OTL-200

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Orchard Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 09, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY